Cysto One PAP
The Cysto One PAP is a molecular test to screen and diagnose low and high grade urinary bladder malignancies as well as urinary tract infections and sexually transmitted diseases.
Cysto One PAP Panel Menu
Performance: 100% sensitivity and 99.8% specificity
Sample Type: Voided Urine
Methodology: Real-Time PCR
Run time: 24 hours
UTI Molecular Assay Panel
STI Assay Molecular Panel
Antimicrobial Resistance Genes
Coagulase negative staphylococci
Enterobacter cloacae complex
Morganella morgani i
Streptococcus agalactiae (group B)
Herpes / HSV1
Herpes / HSV2
Treponema pallidum (Syphillus)
aph(3')-VI, aph(3')-Vla, aph(3')-Vib
Boost effectiveness of patient testing
Urinary Tract Infections (UTIs) account for 83 million doctor visits, 1 million emergency department (ED) visits, and 100,000 hospitalizations annually with an estimated cost of $1 billion annually in the US. Annually, there are over 84,000 new diagnoses of bladder cancer in the U.S.A and 430,000 globally, making it the fourth most prevalent malignancy in men and the fifth most prevalent in woman. Prognosis and mortality is strongly correlated with cancer staging at the time of diagnosis.
Why Cysto One PAP?
The Cysto One PAP screens for presence of Cytokeratin17. Keratin17 is an immunobiomarker which is
involved in the replication cycle of malignant cells. Presence of keratin 17 is a highly specific immunobiomarker for presence of urinary bladder malignancy. In addition Cysto One PAP is designed to test for a host of other infectious urological conditions.
No more, complicated, redundant paperwork or late reports. As a
service oriented, independent and fully certified provider, PCG
Molecular can streamline the process and put the focus where it
belongs– on you, the client. Our policy of speedy and efficient
turnaround for our clients means fast access to the information you
need via all forms of electronic transmittal and increased efficiency
in the day to day operations of your own practice.